Article

AXL Regulates Neuregulin1 Expression Leading to Cetuximab Resistance in Head and Neck Cancer

2021-12-06

Abstract excerpt

<h4>Background: </h4> The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC). Cetuximab is currently the only EGFR-targeting agent approved by the FDA for treatment of HNC; however, intrinsic and acquired resistance to cetuximab is a major problem in the clinic. Our lab previously reported that AXL leads to cetux...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f8bbecc-eedc-532e-8b88-4400b8240f26
DOI: 10.21203/rs.3.rs-951815/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AXL Regulates Neuregulin1 Expression Leading to Cetuximab Resistance in Head and Neck CancerDOI 10.21203/rs.3.rs-951815/v1Read

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.Semantic proximity Read

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signalingSemantic proximity Read

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.Semantic proximity Read

Co-expression of NRP1 and p-EGFR in the prognosis of patients with head and neck squamous cell carcinomaSemantic proximity Read

Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.Semantic proximity Read

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancerSemantic proximity Read

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCCSemantic proximity Read

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and NeckSemantic proximity Read

Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.Semantic proximity Read

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read

Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.Semantic proximity Read